Companies › Design Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Ophthalmology, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DT-168 Unclear mechanism - likely targeting corneal endothelial cell dysfunction or dystrophy pro | – | Phase 2 | Fuchs Endothelial Corneal Dystrophy | Dec 2027 |
| DT-216P2 Unclear - code-named compound for Friedreich's ataxia | – | Phase 1 | Friedreich Ataxia | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06874010 | DT-216P2 | Phase 1 | Friedreich Ataxia | Neurology | Dec 2026 |
| NCT07024693 | DT-168 | Phase 2 | Fuchs Endothelial Corneal Dystrophy | Ophthalmology | Dec 2027 |
Cash and short-term investments of $209m on 2026-09-30; operating cash outflow about $64m a year; runway about 39 months at that burn, to Jan 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Bright Minds Biosciences Bausch & Lomb PolyActiva Ashvattha Therapeutics Belite Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.